Skip to content

Trial Summary

This Randomized Phase 2 Open-label Study will Evaluate the Safety and Efficacy of Zimberelimab (AB122) Monotherapy, AB154 in Combination with Zimberelimab, and AB154 in Combination with Zimberelimab and AB928 in Front-line, PD-L1 Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer.

Acronym:

ARC-7

ACTRN/NCT /ethics:

NCT04262856

Scientific title:

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer.

Sponsor / Cooperative group:

Arcus Biosciences, Inc.

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-05-28
Anticipated End Date2023-06-23

Participating Hospitals

HospitalCalvary Central Districts Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Rohit Joshi
Recruitment StatusRecruiting